Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Invasive Breast Cancer × liposomal doxorubicin × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 47 Ovarian Neoplasms 35 Multiple Myeloma 17 Sarcoma 11 Carcinoma, Ovarian Epithelial 11 Lymphoma 10 Fallopian Tube Neoplasms 10 Triple Negative Breast Neoplasms 9 Neoplasms 7 Lymphoma, Large B-Cell, Diffuse 7 Lymphoma, Non-Hodgkin 6 Hodgkin Disease 6 Recurrence 5 Prostatic Neoplasms 5 Neoplasms, Plasma Cell 5 Sarcoma, Ewing 4 Neoplasm Metastasis 4 Burkitt Lymphoma 4 Rhabdomyosarcoma 3 Pancreatic Neoplasms 3 Osteosarcoma 3 Lymphoma, T-Cell, Peripheral 3 Lymphoma, Mantle-Cell 3 Breast Neoplasms, Male 3 Uterine Cervical Neoplasms 2 Solid Tumors 2 Lymphoma, T-Cell, Cutaneous 2 Lymphoma, T-Cell 2 Lymphoma, Large-Cell, Immunoblastic 2 Lymphoma, Follicular 2

Interventions

Surgical Procedures, Operative 2 Paclitaxel 2 Doxorubicin 2 Cyclophosphamide 2 Carboplatin 2 pertuzumab 1 liposomal doxorubicin 1 cemiplimab 1 atezolizumab 1 Trastuzumab 1 Radiotherapy 1 Magnetic Resonance Spectroscopy 1 Indocyanine Green 1 Anastrozole 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04243616 2025-09-05

CemiHALT

Medical College of Wisconsin

Phase 2 Active not recruiting

Invasive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡